급성 췌장염 : 시장 인사이트, 역학 및 시장 예측(2036년)

Acute Pancreatitis Insights and Trends

• The acute pancreatitis disease landscape is characterized by sudden inflammation of the pancreas resulting from premature activation of digestive enzymes, leading to pancreatic injury and systemic inflammatory response. This condition is well described in published clinical literature and major gastroenterology guidelines.
• Clinically, patients typically present with acute upper abdominal pain radiating to the back, nausea, vomiting, and fever, accompanied by elevated serum lipase and amylase, with lipase considered the more specific marker. While the majority of cases are mild and self-limiting, approximately 15-20% progress to severe acute pancreatitis, which is associated with pancreatic necrosis, infected necrosis, and multi-organ failure, contributing significantly to morbidity and mortality.
• The leading causes are gallstone disease and alcohol use, which together account for the majority of cases globally, consistent across epidemiological studies. Additional risk factors include hypertriglyceridemia, obesity, diabetes, infections, trauma, and drug-induced causes, reflecting its strong association with metabolic and lifestyle-related conditions.
• Diagnosis is based on the widely accepted Revised Atlanta Classification, requiring at least two of the following: characteristic abdominal pain, elevated pancreatic enzymes, and imaging findings on ultrasound or contrast-enhanced CT, which are also used for severity assessment and detection of complications such as necrosis or fluid collections.
• Management remains primarily supportive care-based, centered on early aggressive intravenous fluid resuscitation, analgesia, and early enteral nutrition, as recommended in international guidelines. Etiology-specific interventions, such as endoscopic retrograde cholangiopancreatography (ERCP) for gallstone-related disease, are used in selected cases, while intensive care support is required for severe disease and complications such as sepsis and organ failure.
• Despite extensive research, there are currently no FDA-approved disease-modifying therapies for acute pancreatitis, and treatment remains focused on supportive and complication-driven care. Investigational approaches are exploring inflammatory pathway modulation, immune response regulation, and pancreatic cell protection, but none have yet demonstrated consistent clinical benefit in late-stage trials.

DelveInsight's 'Acute Pancreatitis - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the acute pancreatitis, historical and forecasted epidemiology, as well as the Acute Pancreatitis market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

The Acute Pancreatitis market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates Acute Pancreatitis patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in Acute Pancreatitis and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Acute Pancreatitis Market

Increasing Incidence of Gallstone-, Alcohol-, and Metabolic Syndrome Associated Acute Pancreatitis

The acute pancreatitis market is experiencing significant growth, driven by the increasing global prevalence of key risk factors such as gallstone disease, excessive alcohol consumption, obesity, hypertriglyceridemia, and metabolic syndrome. Additionally, the rising incidence of diabetes, an aging population, sedentary lifestyles, and unhealthy dietary patterns are contributing to a higher rate of hospitalizations and an escalating clinical burden associated with acute pancreatitis.

Advancements in Targeted Therapies

The acute pancreatitis treatment landscape is evolving rapidly, supported by growing research efforts focused on anti-inflammatory, immunomodulatory, and organ-protective therapies designed to reduce pancreatic inflammation, minimize systemic complications, and improve disease outcomes. In addition, emerging pipeline therapies targeting inflammatory cytokines, trypsin activation pathways, oxidative stress, and pancreatic necrosis are expected to drive future therapeutic innovation beyond the current standard of supportive care management.

Growing Focus on Early Intervention and Severe Disease Management

Growing recognition of the importance of early diagnosis, aggressive fluid resuscitation, nutritional support, and prevention of systemic complications is contributing to significant improvements in acute pancreatitis management. At the same time, the development of targeted therapies for severe acute pancreatitis, pancreatic necrosis, and multiorgan dysfunction is expected to enhance clinical outcomes and encourage the adoption of more advanced treatment strategies for high-risk patient populations.

Acute Pancreatitis Understanding and Treatment Algorithm

Acute Pancreatitis Overview and Diagnosis

Acute pancreatitis is a sudden inflammatory condition of the pancreas caused by premature activation of pancreatic enzymes, leading to pancreatic injury and systemic inflammation. The disease commonly presents with severe upper abdominal pain radiating to the back, nausea, vomiting, fever, and elevated pancreatic enzyme levels. Gallstones and chronic alcohol consumption are the leading causes, while hypertriglyceridemia, infections, trauma, and certain medications may also contribute. Although many cases are mild and self-limiting, severe acute pancreatitis can result in pancreatic necrosis, multiorgan failure, sepsis, and significant mortality. Diagnosis is based on clinical symptoms, serum amylase/lipase levels, and imaging studies such as ultrasound or CT scan. Current management primarily involves supportive care, including intravenous fluids, pain management, nutritional support, and treatment of complications, as there are currently no FDA-approved therapies specifically indicated for acute pancreatitis.

Acute Pancreatitis Diagnosis

Diagnosis of acute pancreatitis is primarily based on clinical presentation, elevated pancreatic enzyme levels, and imaging findings. Diagnosis is generally confirmed when patients present with characteristic upper abdominal pain along with elevated serum amylase and lipase levels, particularly lipase, which is considered more specific for pancreatic injury. Imaging techniques such as abdominal ultrasound and contrast-enhanced CT scan are commonly used to identify pancreatic inflammation, gallstones, necrosis, fluid collections, and disease severity. Additional laboratory investigations, including liver function tests, triglyceride levels, inflammatory markers, and renal function assessment, help evaluate underlying causes, systemic complications, and overall disease severity.

Acute Pancreatitis Treatment

Treatment of acute pancreatitis primarily focuses on supportive care, management of underlying causes, and prevention of local and systemic complications. Initial treatment typically includes aggressive intravenous fluid resuscitation, pain management with analgesics, and early nutritional support, preferably through enteral feeding. In patients with gallstone-associated pancreatitis, ERCP may be performed to relieve biliary obstruction. Antibiotics are generally reserved for confirmed infections or infected pancreatic necrosis rather than routine prophylactic use. In severe cases, patients may require intensive care support, drainage procedures, or surgical intervention for pancreatic necrosis and related complications.

Acute Pancreatitis Unmet Needs

The section "unmet needs of acute pancreatitis" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of FDA-approved disease-specific therapies

2. Need for early diagnosis and reliable severity prediction tools

3. Limited treatment options for severe and necrotizing acute pancreatitis

4. High risk of systemic inflammation, organ failure, and mortality

5. Need for targeted anti-inflammatory and pancreatic protective therapies, and others.....

Acute Pancreatitis Epidemiology

Key Findings from Acute Pancreatitis Epidemiological Analysis and Forecast

• Global incidence of acute pancreatitis is estimated at 30-50 cases per 100,000 population per year (~300-500 per million), based on large population registries across Europe and the US.
• Recent real-world national data (e.g., UK and European datasets) estimate an incidence of approximately 400-500 cases per million population, with an annual increase of ~2-3%, reflecting a growing healthcare burden.
• Gallstones and chronic alcohol consumption account for the majority of acute pancreatitis cases, collectively contributing to approximately 70-80% of disease burden in most published epidemiology studies.
• The incidence of acute pancreatitis varies geographically, with higher disease burden observed in regions characterized by elevated alcohol consumption, greater prevalence of gallstone disease, and increasing metabolic risk factors such as obesity and hypertriglyceridemia.
• Although most patients experience mild and self-limiting disease, approximately 15-20% of patients develop severe acute pancreatitis, which is associated with pancreatic necrosis, organ failure, prolonged hospitalization, and increased mortality.
• Acute pancreatitis-related mortality remains significant in severe disease, particularly among patients with infected pancreatic necrosis or persistent multiorgan failure despite improvements in critical care management.
• Acute pancreatitis accounts for ~1-2% of all hospital admissions and is one of the most common gastrointestinal causes of emergency hospitalization.

Acute Pancreatitis Drug Analysis & Competitive Landscape

The Acute Pancreatitis drug chapter provides a detailed, market-focused review of the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the acute pancreatitis treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the acute pancreatitis therapeutics market.

Acute Pancreatitis Pipeline Analysis

Auxora (CM-5480): CalciMedica

Auxora is a novel drug developed by CalciMedica for the treatment of acute pancreatitis. It is a potent and selective small molecule inhibitor of Orai1-containing CRAC channels that is being developed for use in patients with acute inflammatory and immunologic illnesses. CRAC channels are found on many cell types, including immune system cells, endothelium cells and pancreatic acinar cells, where aberrant activation of these channels may play a key role in the pathobiology of acute and chronic inflammatory syndromes.

RABI-767: Arrivo Bioventures

RABI-767 is a small molecule lipase inhibitor that has shown profound efficacy in the treatment of acute pancreatitis in multiple clinically relevant mouse models.

Acute Pancreatitis Key Players, Market Leaders, and Emerging Companies

• CalciMedica
• Arrivo Bioventures, and others...

Acute Pancreatitis Drug Updates

• In March 2026, CalciMedica announced to continue constructive discussions with the US Food and Drug Administration (FDA) regarding the pivotal program for Auxora in acute pancreatitis and expects to finalize the program design in the first half of 2026.
• In November 2025, Arrivo Bioventures announced to present early clinical data on RABI-767 at the 2025 American Pancreatic Association annual meeting.
• In October 2025, CalciMedica announced that they and Telperian have entered into a collaboration to integrate Telperian's advanced AI platform into the analysis of data from completed Auxora clinical trials. The objective of this partnership is to generate deeper insights from existing trial data, including identifying patient subgroups and treatment effects, which will help refine the design of CalciMedica's planned pivotal trial in acute pancreatitis. The findings are also expected to support ongoing regulatory interactions with the FDA as part of Auxora's late-stage development strategy.

Drug Class Insights

Acute Pancreatitis Market Outlook

The acute pancreatitis market is currently characterized by a high and rising disease burden, driven by increasing prevalence of gallstone disease, alcohol consumption, obesity, hypertriglyceridemia, and metabolic syndrome. The growing global incidence of diabetes, aging populations, and sedentary lifestyles is further contributing to higher hospitalization rates and an expanding clinical and economic burden of disease.

Despite its significant healthcare impact, acute pancreatitis remains a largely supportive-care driven market, as there are currently no FDA-approved disease-modifying therapies specifically indicated for acute pancreatitis. Standard management continues to rely on intravenous fluid resuscitation, pain control, nutritional support, and treatment of underlying etiologies such as gallstones or alcohol use. This creates a substantial unmet need, particularly in patients who progress to moderate-to-severe disease and necrotizing acute pancreatitis.

The treatment landscape is gradually evolving with increasing focus on targeted and mechanism-based therapies aimed at reducing pancreatic inflammation, systemic immune activation, and multi-organ dysfunction. Emerging pipeline therapies are investigating key disease pathways, including inflammatory cytokines, immune modulation, calcium signaling dysregulation, oxidative stress, and acinar cell injury mechanisms. In parallel, biologics and novel small molecules targeting severe acute pancreatitis and pancreatic necrosis are being developed to improve outcomes in high-risk hospitalized patients.

Growing clinical emphasis on early risk stratification, rapid intervention, and prevention of systemic complications is reshaping management paradigms. Advances in diagnostic imaging, biomarkers, and critical care protocols are expected to enable earlier identification of patients at risk of severe disease progression, thereby improving clinical decision-making and outcomes.

• Gallstone-associated and alcohol-associated acute pancreatitis together account for the majority of global disease burden.
• Severe acute pancreatitis develops in approximately 15-20% of patients and continues to represent the area of greatest unmet need within the treatment landscape.
• The lack of approved targeted pharmacological therapies presents a significant market opportunity for first-in-class agents aimed at reducing systemic inflammation, pancreatic necrosis, and multi-organ dysfunction.
• Increasing hospitalization rates and the growing burden of obesity, metabolic syndrome, and hypertriglyceridemia are expected to further expand the acute pancreatitis patient pool and drive future market demand for targeted therapies.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Acute Pancreatitis (2022-2036 Forecast)

Acute pancreatitis management is primarily centered on supportive care, with aggressive intravenous fluid resuscitation, effective pain control, and early enteral nutritional support forming the cornerstone of treatment to preserve organ perfusion, limit systemic inflammation, and improve patient outcomes. Therapeutic strategies are increasingly guided by the underlying disease etiology. In gallstone-induced acute pancreatitis, endoscopic retrograde cholangiopancreatography (ERCP) is utilized to relieve biliary obstruction and reduce disease progression, whereas alcohol-associated pancreatitis requires sustained alcohol cessation and relapse prevention measures to minimize recurrence risk. In patients with hypertriglyceridemia-induced disease, lipid-lowering interventions such as insulin infusion or apheresis may be necessary in severe presentations. Management becomes significantly more complex in severe acute pancreatitis cases complicated by pancreatic necrosis, infected necrosis, or multi-organ dysfunction syndrome, often requiring intensive care support, organ support therapies, image-guided drainage, and selective surgical necrosectomy. Antibiotic use remains restricted to confirmed or strongly suspected infected necrosis, reflecting the continued emphasis on evidence-based and complication-specific treatment approaches.

• Emerging targeted and mechanism-based therapies: The pipeline is focused on anti-inflammatory, immune-modulating, and organ-protective approaches aimed at reducing pancreatic inflammation, systemic immune activation, and progression to severe disease. Investigational strategies include modulation of cytokine signaling pathways, calcium-dependent cellular injury mechanisms, oxidative stress reduction, and acinar cell protection.
• Shift toward early risk stratification and precision management: Advances in biomarkers, imaging modalities, and critical care scoring systems are improving the ability to identify patients at risk of severe acute pancreatitis early in the disease course. This is enabling more proactive intervention strategies aimed at preventing necrosis, organ failure, and mortality.

Acute Pancreatitis Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the acute pancreatitis drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Detailed insights of emerging therapies' drug uptake is included in the report.

Market Access and Reimbursement of Acute Pancreatitis

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Acute Pancreatitis Therapies Price Scenario & Trends

Pricing and analogue assessment of acute pancreatitis therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report...

Industry Experts and Physician Views for Acute Pancreatitis

To keep up with acute pancreatitis market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the emerging acute pancreatitis therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in acute pancreatitis, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights at the country level. Centers such as the Johns Hopkins University, Universitatsmedizin Berlin, Osaka University Hospital, Erasmus University Medical Center Rotterdam etc., were contacted. Their opinion helps understand and validate current and emerging acute pancreatitis therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in Acute Pancreatitis.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT Analysis of Acute Pancreatitis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of acute pancreatitis, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Acute Pancreatitis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Acute Pancreatitis market.

Report Insights

• Acute Pancreatitis Patient Population Forecast
• Acute Pancreatitis Therapeutics Market Size
• Acute Pancreatitis Pipeline Analysis
• Acute Pancreatitis Market Size and Trends
• Acute Pancreatitis Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Acute Pancreatitis Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Acute Pancreatitis Treatment Addressable Market (TAM)
• Acute Pancreatitis Competitive Landscape
• Acute Pancreatitis Major Companies Insights
• Acute Pancreatitis Price Trends and Analogue Assessment
• Acute Pancreatitis Therapies Drug Adoption/Uptake
• Acute Pancreatitis Therapies Peak Patient Share Analysis

Report Assessment

• Acute Pancreatitis Current Treatment Practices
• Acute Pancreatitis Unmet Needs
• Acute Pancreatitis Clinical Development Analysis
• Acute Pancreatitis Emerging Drugs Product Profiles
• Acute Pancreatitis Market Attractiveness
• Acute Pancreatitis Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the acute pancreatitis market size, the market size by therapies, the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Acute Pancreatitis?
• What are the disease risks, burdens, and unmet needs of Acute Pancreatitis? What will be the growth opportunities across the 7MM concerning the patient population with Acute Pancreatitis?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Acute Pancreatitis? What are the current guidelines for treating acute pancreatitis in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Acute Pancreatitis market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Acute Pancreatitis

4. Key Events of Acute Pancreatitis

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences And Meetings
• 4.3. Key Transactions And Collaborations
• 4.4. News Flow

5. Epidemiology and Market Methodology of . Acute Pancreatitis

6. Acute Pancreatitis Market Overview at a Glance

• 6.1. Clinical Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of Acute Pancreatitis By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of Acute Pancreatitis By Therapies (%) in the 7MM in 2036

7. Disease Background And Overview of Acute Pancreatitis

• 7.1. Introduction
• 7.2. Signs and Symptoms
• 7.3. Stages and Clinical presentation of Acute Pancreatitis
• 7.4. Causes
• 7.5. Pathogenesis
• 7.6. Diagnosis
  • 7.6.1. Diagnostic Algorithm
  • 7.6.2. Diagnostic Approach
  • 7.6.3. Diagnostic Recommendations
• 7.7. Differential Diagnosis

8. Treatment and Guidelines of Acute Pancreatitis

• 8.1. General Management
• 8.2. Treatment Algorithm
• 8.3. Treatment Recommendations

9. Epidemiology and Patient Population of Acute Pancreatitis

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. Total Incident Cases of Acute Pancreatitis in the 7MM
  • 9.2.2. Treated Cases of Acute Pancreatitis in the 7MM
• 9.3. The US
  • 9.3.1. Total Incident Cases of Acute Pancreatitis in the US
  • 9.3.2. Etiology-specific Incident Cases of Acute Pancreatitis in the US
  • 9.3.3. Severity-specific Incident Cases of Acute Pancreatitis in the US
  • 9.3.4. Gender-specific Incident Cases of Acute Pancreatitis in the US
  • 9.3.5. Treated Cases of Acute Pancreatitis in the US
• 9.4. EU4 and the UK
  • 9.4.1. Total Incident Cases of Acute Pancreatitis in the EU4 and the UK
  • 9.4.2. Etiology-specific Incident Cases of Acute Pancreatitis in the EU4 and the UK
  • 9.4.3. Severity-specific Incident Cases of Acute Pancreatitis in the EU4 and the UK
  • 9.4.4. Gender-specific Incident Cases of Acute Pancreatitis in the EU4 and the UK
  • 9.4.5. Treated Cases of Acute Pancreatitis in the EU4 and the UK
• 9.5. Japan
  • 9.5.1. Total Incident Cases of Acute Pancreatitis in the Japan
  • 9.5.2. Etiology-specific Incident Cases of Acute Pancreatitis in the Japan
  • 9.5.3. Severity-specific Incident Cases of Acute Pancreatitis in the Japan
  • 9.5.4. Gender-specific Incident Cases of Acute Pancreatitis in the Japan
  • 9.5.5. Treated Cases of Acute Pancreatitis in the Japan

10. Patient Journey of Acute Pancreatitis

11. Emerging Therapies of Acute Pancreatitis

• 11.1. Competitive Landscape of Emerging Therapies
• 11.2. Auxora (CM-5480): CalciMedica
  • 11.2.1. Product Description
  • 11.2.2. Other Developmental Activities
  • 11.2.3. Clinical Development
  • 11.2.4. Safety and Efficacy
  • 11.2.5. Analyst's View

12. Acute Pancreatitis: 7MM Analysis

• 12.1. Key Findings
• 12.2. Market Outlook
• 12.3. Conjoint Analysis
• 12.4. Key Market Forecast Assumptions
  • 12.4.1. Cost Assumptions and Rebates
  • 12.4.2. Pricing Trends
  • 12.4.3. Analogue Assessment
  • 12.4.4. Launch Year and Therapy Uptakes
• 12.5. Total Market Size of Acute Pancreatitis in the 7MM
• 12.6. The United States Market Size
  • 12.6.1. Total Market Size of Acute Pancreatitis in the United States
  • 12.6.2. Market Size of Acute Pancreatitis by Therapies in the United States
• 12.7. EU4 and the UK Market Size
  • 12.7.1. Total Market Size of Acute Pancreatitis in EU4 and the UK
  • 12.7.2. Market Size of Acute Pancreatitis by Therapies in EU4 and the UK
• 12.8. Japan Market Size
  • 12.8.1. Total Market Size of Acute Pancreatitis in Japan
  • 12.8.2. Market Size of Acute Pancreatitis by Therapies in Japan

13. Unmet Needs of Acute Pancreatitis

14. SWOT Analysis of Acute Pancreatitis

15. KOL Views of Acute Pancreatitis

• 15.1. Expert/KOL Interview Highlights

16. Market Access and Reimbursement of Acute Pancreatitis

• 16.1. United States
  • 16.1.1. Centre for Medicare and Medicaid Services (CMS)
• 16.2. EU4 and the UK
  • 16.2.1. Germany
  • 16.2.2. France
  • 16.2.3. Italy
  • 16.2.4. Spain
  • 16.2.5. United Kingdom
• 16.3. Japan
• 16.4. Summary and comparison of Market Access and Pricing Policy Developments in 2025
• 16.5. Market Access and Reimbursement of Acute Pancreatitis Therapies

17. Appendix

• 17.1. Bibliography
• 17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight